Cereno Scientific takes the next step towards phase IIb study in PAH
10 november, 13:40
10 november, 13:40
Cereno Scientific has submitted the trial protocol for its planned global phase IIb trial of its drug candidate CS1 to the U.S. Food and Drug Administration (FDA). The submission is an important step in the company's work to develop new treatments for pulmonary arterial hypertension (PAH), a rare and serious disease that affects the blood vessels in the lungs.
Read the article at biostock.se:
Cereno Scientific takes the next step towards phase IIb study in PAH
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
10 november, 13:40
Cereno Scientific has submitted the trial protocol for its planned global phase IIb trial of its drug candidate CS1 to the U.S. Food and Drug Administration (FDA). The submission is an important step in the company's work to develop new treatments for pulmonary arterial hypertension (PAH), a rare and serious disease that affects the blood vessels in the lungs.
Read the article at biostock.se:
Cereno Scientific takes the next step towards phase IIb study in PAH
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Börsprognos
Aktieanalyser
Rapporter
Förvaltarnas investeringar
Placerapodden
Aktieanalyser
Rapporter
Förvaltarnas investeringar
Placerapodden
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 780,58